Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study

David M. Kendall, Cindy J. Rubin, Pharis Mohideen, Jean Marie Ledeine, Rene Belder, Jorge Gross, Paul Norwood, Michael O'Mahony, Kenneth Sall, Greg Sloan, Anthony Roberts, Fred T. Fiedorek, Ralph A. DeFronzo

Research output: Contribution to journal › Article › peer-review

136 Scopus citations

Fingerprint

Dive into the research topics of 'Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science